Part 2: Parsaclisib plus Pembrolizumab
DLTs, TEAEs
No DLTs were reported in patients enrolled in Part 2. All patients experienced ≥1 TEAE (Nine patients (33.3%) in Part 2 experienced TEAEs leading to discontinuation of parsaclisib, and 8 patients (29.6%) had TEAEs leading to discontinuation of pembrolizumab.